化学
欧洲联盟
药理学
药品
药品审批
制药工业
组合化学
生化工程
业务
国际贸易
工程类
医学
作者
Scott P. France,Erick A. Lindsey,Emma L. McInturff,Simon Berritt,Daniel W. Carney,Jacob C. DeForest,Sarah J. Fink,Andrew C. Flick,Tony Gibson,Kaitlyn Gray,Amber M. Johnson,Carolyn A. Leverett,Yiyang Liu,Subham Mahapatra,Rebecca B. Watson
标识
DOI:10.1021/acs.jmedchem.3c02374
摘要
In 2022, 23 new small molecule chemical entities were approved as drugs by the United States FDA, European Union EMA, Japan PMDA, and China NMPA. This review describes the synthetic approach demonstrated on largest scale for each new drug based on patent or primary literature. The synthetic routes highlight practical methods to construct molecules, sometimes on the manufacturing scale, to access the new drugs. Ten additional drugs approved in 2021 and one approved in 2020 are included that were not covered in the previous year's review.
科研通智能强力驱动
Strongly Powered by AbleSci AI